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Multiple myeloma (MM) is a hematological malignancy that remains incurable because most patients will eventually relapse or
become refractory to the treatments. Although the treatments have improved, the major problem in MM is the resistance to
therapy. Novel agents are currently in development for the treatment of relapsed/refractory MM, including immunomodulatory
drugs, proteasome inhibitors, monoclonal antibodies, cell signaling targeted therapies, and strategies targeting the tumor
microenvironment. We have previously reviewed in detail the contemporary immunomodulatory drugs, proteasome inhibitors,
and monoclonal antibodies therapies for MM. Therefore, in this review, we focused on the role of molecular targeted therapies in
the treatment of relapsed/refractory multiple myeloma, including cell signaling targeted therapies (HDAC, PI3K/AKT/mTOR, p38
MAPK,Hsp90,Wnt,Notch,Hedgehog, and cell cycle) and strategies targeting the tumormicroenvironment (hypoxia, angiogenesis,
integrins, CD44, CXCR4, and selectins). Although these novel agents have improved the therapeutic outcomes for MM patients,
further development of new therapeutic agents is warranted.
1. Introduction
Multiple myeloma (MM) is a hematological malignancy
that remains incurable because most patients will eventually
relapse or become refractory to the treatments [1]. Although
the treatments have improved, the major problem in MM is
the resistance to therapy [2]. Novel agents are currently in
development for the treatment of relapsed/refractory MM,
including immunomodulatory drugs, proteasome inhibitors,
monoclonal antibodies, cell signaling targeted therapies,
and strategies targeting the tumor microenvironment. These
agents have demonstrated antitumor activity in relapsed/
refractory MM, and rationally combinations of them are
being tested in the clinic to improve the clinical outcomes.We
have recently reviewed in detail the contemporary immuno-
modulatory drugs, proteasome inhibitors, and monoclonal
antibodies therapies for MM [3].
This review focuses onmolecularly targeted therapies that
are currently evaluated in clinical trials in the treatment of
relapsed/refractory MM patients, which are based on unique
cell signaling pathways activated in MM and not in nor-
mal cells, including inhibitors of HDAC, PI3K/AKT/mTOR,
p38 MAPK, Hsp90, Wnt, Notch, Hedgehog, and cell cycle.
Despite promising results that have been recently obtained,
the activity of these agents used alone is still limited and
can be significantly enhanced by combination with tradi-
tional chemotherapeutic drugs. In addition, in this review,
we focused on targeting tumor microenvironmental factors
(such as interactions between MM and BM components
including extracellular matrix, stromal cells, and endothelial
cells) as a novel therapeutic strategy in MM.
2. Histone Deacetylase (HDAC) Inhibitors
Histone acetylation modulates gene expression, cellular dif-
ferentiation, and survival and is regulated by histone acetyl-
transferases and histone deacetylases (HDACs). Inhibition
of HDAC activity promotes differentiation, cell cycle arrest,
and/or apoptosis of tumor cells [4]. The effect of HDAC
inhibitors on multiple pathways also allows for good comple-
mentary activity during combination with other antitumor
agents, leading to synergy. Therefore, inhibition of HDAC
can reverse epigenetic silencing of genes that regulate tumor
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growth and survival, such as genes that promote apoptosis
and regulate the cell cycle or angiogenesis.
2.1. Panobinostat. Panobinostat (LBH589) has potent
inhibitory activity at low nanomolar concentrations against
all classes I, II, and IV purified recombinant HDAC enzymes,
suggesting true pan-HDAC activity [5]. The initial phase
II study of single-agent panobinostat demonstrated modest
antimyeloma activity in heavily pretreated patients who
were refractory to at least two prior lines of therapy,
including bortezomib and lenalidomide or thalidomide,
with one partial response (PR) and one minimal response
observed in 38 patients; however, these responses were
maintained for 19 and 28 months, respectively, following
initiation of therapy, with good tolerability observed [6].
Panobinostat has been also investigated in combination
with other established agents (lenalidomide, melphalan, or
bortezomib) for the treatment of relapsed/refractory MM.
In a recently published phase II trial, panobinostat was
examined in combination with melphalan, thalidomide,
and prednisone in relapsed/refractory MM patients; at
least PR was observed in 38.5% of patients; however, the
treatment was challenging in terms of hematologic toxicities,
with reported neutropenia (71%) and thrombocytopenia
(35.5%) [7]. In a preliminary demographic and blinded safety
results of a phase III study (PANORAMA 1) in patients with
relapsed MM it was shown that panobinostat in combination
with bortezomib has shown clinical activity in relapsed and
refractory MM patients, with no new or unexpected adverse
effects (AEs) [8]. The triple combination of panobinostat
and dexamethasone with bortezomib or lenalidomide also
demonstrates a similar mechanistic profile and a synergistic
effect on MM via the reduction of tumor burden, inhibition
of disease progression, and preservation of bone integrity [9].
2.2. Vorinostat. Vorinostat (or suberoylanilide hydroxamic
acid, SAHA) is also a pan-HDAC of HDAC classes I, II and
IV [10]. Vorinostat caused apoptosis and molecular changes
in MM cells and a reduction of IL-6 production by bone
marrow stromal cells [11]. Vorinostat induces accumulation of
acetylated core nucleosomal histones, with related induction
of apoptosis in MM cells, including in cells resistant to
conventional chemotherapies [4]. Vorinostat treatment of
MM cells was associated with increased p21 and p53 protein
levels, downregulation of antiapoptotic molecules (caspases
inhibitors), and suppression of activity of the proteasome and
expression of its subunits [4]. Vorinostat was also shown to
enhance the activity of other proapoptotic agents, including
dexamethasone and thalidomide derived immunomodula-
tory drugs (IMiDs), such as lenalidomide and pomalidomide.
A phase I study of lenalidomide, bortezomib, and dexam-
ethasone in combination with vorinostat showed therapeutic
efficacy and improved tolerability. The overall response rate
(PR or better) was 52% and the complete remission (CR) rate
of 28% [12].
2.3. Rocilinostat. Rocilinostat (ACY-1215) is a HDAC6 in-
hibitor, which targets the aggresomal protein degradation
systems. Targeting both proteasomal and aggresomal pro-
tein degradation systems with proteasome and HDAC6
inhibitors, respectively, induces synergistic antitumor activity
in MM [13]. In vitro and in vivo studies showed significant
and synergistic anti-MM activity of rocilinostat in combina-
tion with bortezomib; the combination of rocilinostat and
bortezomib showed a potential beneficial role of HDAC6
inhibition on MM-related bone disease [14].
3. PI3K/AKT/mTOR Pathway Inhibitors
The PI3K pathway mediates proliferative and antiapop-
totic signals in MM through both cytokine-dependent and
cytokine-independent mechanisms, and the activity of the
pathway was shown to increase with the progression of
the disease [15]. Therefore, targeting the PI3K has been a
desirable target inMM since its identification as an oncogene
and as the most frequently mutated oncogene in breast
and endometrial cancers [16]. Activated AKT subsequently
modulates the phosphorylation of several substrates involved
in the regulation of cell survival, cell cycle progression, and
cellular growth [17]. The best-studied downstream substrate
of AKT and one of the most commonly mutated pathways
in cancer is the serine/threonine kinase mTOR (mammalian
target of rapamycin).
AKT indirectly activates mTOR, a complicated check-
point of cellular growth influenced by growth factor sig-
naling, adenosine monophosphate levels, and nutrient and
O2 availability [18]. mTOR consists of 2 distinct multi-
molecular complexes, mTOR complex 1 (mTORC1), and
complex 2 (mTORC2). mTORC1 activity leads to increased
mRNA translation, protein synthesis, and cellular prolifera-
tion. mTORC2 is involved in regulation of the cytoskeleton
and is upstream from and directly to phosphorylates AKT
[19]. mTORC1 inhibition can lead to activation of the PI3K
pathway due to mTORC2 negative feedback, resulting in
phosphorylation of AKT [20].
3.1. Perifosine. Perifosine (KRX-0401) is an oral bioactive
alkylphospholipid that is thought to target cell membranes
and modulate multiple signaling pathways, including inhibi-
tion ofAkt and promotion of apoptosis inMMcells [21]. Inhi-
bition of AKT phosphorylation downregulates signal trans-
duction via the PI3K/AKT/mTOR pathway, a key regulator of
cellular growth and survival. Preclinical studies have shown
that perifosine has cytotoxic activity against MM cell lines,
and it enhances the cytotoxic effects of dexamethasone, dox-
orubicin, melphalan, and bortezomib by promoting apop-
tosis [22]. A phase I study with perifosine in combination
with lenalidomide and dexamethasone was developed, and
patients tolerated the treatmentwell withmanageable toxicity
and with encouraging clinical activity demonstrated by an
ORR of 50% [23]. A multicenter phase I/II trial evaluated
84 patients with relapsed or relapsed/refractory MM treated
with perifosine in combination with bortezomib with or
without dexamethasone.Therapy was generally well tolerated
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and it was shown that perifosine in combination with dexam-
ethasone has activity in relapsed or relapsed/refractory MM;
an overall response rate (ORR) of 41% was demonstrated,
including an ORR of 65% in bortezomib-relapsed patients
and 32% in bortezomib-refractory patients [24].
3.2. Other PI3K Inhibitors. Recently, many PI3K inhibitors
are under investigation including a highly selective class
I PI3K inhibitor, GDC-0941 [25], or a specific PI3KCA
inhibitor, BYL719 [26]; all of them with potent antitumor
activity against MM.
3.3. Rapamycin and Analogues. Rapamycin and some ana-
logues (temsirolimus orCCI-779 and everolimus or RAD001)
are inhibitors of mTOR and have shown preclinical potential
as MM therapies. There may also be a role of combination
therapy with this class in that synergy has been demonstrated
in combination with other therapies. A phase I/II study
studied temsirolimus combined with bortezomib (both IV
on a weekly schedule) in a heavily pretreated population,
showing that this combination was well-tolerated with pre-
dominantly hematologic toxicity and that mTOR inhibitors
could have a role in combination with weekly bortezomib for
the treatment of patients with relapsed and refractory MM,
with a partial response or better of 33% [27]. Everolimus given
orally at doses of 5mg to 10mg daily showed an acceptable
safety profile in heavily pretreatedMMpatients in a phase I/II
study as single agent, with antimyeloma activity documented
in 5 out of 7 evaluable patients [28].
Rapamycin and its analogs have shown limited activ-
ity in MM, likely because of the lack of inhibition of
mTORC2. Then, INK128, a dual mTORC1/2 inhibitor, is a
new therapeutic agent against MM. It was shown that dual
mTORC1/2 inhibition is much more active than mTORC1
inhibition alone (rapamycin) [29]. NVP-BEZ235 is a dual
pan inhibitor of PI3K/Akt/mTOR pathways at the levels of
PI3K and mTOR, which inhibits growth and proliferation in
MM. Moreover, synergism studies revealed synergistic and
additive activity of NVP-BEZ235 together with melphalan,
doxorubicin, and bortezomib [30].
4. p38 MAPK Inhibitors
p38 mitogen-activated protein kinase (MAPK) is a serine-
threonine kinase that is activated via phosphorylation, which
is induced by a variety of environmental stresses and inflam-
matory cytokines [31]. p38 is constitutively activated in
human myeloma and it has been implicated in osteoclast
and osteoblast activity and bone destruction [32]. The effect
of a p38 alpha-selective MAPK inhibitor, such as SCIO-
469 (indole-5-carboxamide, ATP-competitive inhibitor), or
its structural analog, SD-282 (indole-5-carboxamide, ATP-
competitive inhibitor), reduced human myeloma cell growth
in vivo at early and advanced phases of the disease and
also provided evidence of potential for cotherapy with dex-
amethasone [33]. LY2228820, a p38 MAPK inhibitor, sig-
nificantly enhanced the toxicity of bortezomib and reduced
osteoskeletal events [34]; anyway, more studies in that path-
way should be developed to overcome the treatment in MM
patients.
5. Heat-Shock Protein 90 Inhibitors
Heat-shock protein 90 (Hsp90) presented as an important
target in the treatment of MM, based on its function as
a molecular chaperone for proteins that are mutated or
overexpressed in tumor cells [35]. Hsp90 facilitates the intra-
cellular trafficking, conformational maturation, and three-
dimensional folding of intracellular proteins involved in cell
proliferation, survival, and drug resistance. Tanespimycin, an
Hsp90 inhibitor, reduces tumor cell survival in vitro. In MM,
Hsp90 inhibition affects multiple proteins that contribute to
tumor cell survival, including the IL-6 receptor and elements
of the PI3K/Akt and MAPK signaling pathways. Hsp90
inhibition also abrogates the protective effect of bonemarrow
stromal cells and inhibits angiogenesis. Tanespimycin acts
synergistically with the proteasome inhibitor bortezomib in
MM cells. The combination of tanespimycin and bortezomib
has demonstrated significant and durable responses with
acceptable toxicity in a phase I/II study in patients with
relapsed and refractory MM. This study has shown low rates
of PN, and ORR of 27%, including 12% minimal responses
(MR) [36].
6. Wnt, Notch, and Hedgehog (Hh)
Pathway Inhibitors
Cancer stem cells use many of the same signaling pathways
that are found in normal stem cells, such as Wnt, Notch,
and Hedgehog (Hh). New experimental agents are being
developed to inhibit the Wnt, Notch, and Hh signaling path-
ways; although still early in development, this new approach
of targeting both the bulk tumor and cancer stem cells
populations may provide a more effective way of inhibiting
tumor relapse and metastasis [37].
6.1.Wnt Inhibitors. Wnt proteins are conserved glycoproteins
that serve as ligands for the Frizzled (Fz) transmembrane
receptor and aberrant Wnt signaling has been reported in
MM [37]. It was shown that AV-65, a novel Wnt/𝛽-catenin
signal inhibitor, successfully suppressed progression of MM
[38]. Myeloma cells suppress osteoblast differentiation by
secretingWnt signaling inhibitors such as dickkopf 1 (DKK1)
and soluble frizzled receptor-like proteins (sFRPs) [39]. Eph
receptors belong to a subfamily of receptor tyrosine kinases
activated by ligands called ephrins (Eph receptor interacting
proteins). Since Eph receptors are a target of Wnt signaling
in some tumors [40], decreased Wnt signaling in myeloma
bone may suppress osteoblast differentiation, at least in part,
by reducing Eph expression.
6.2. Notch Inhibitors. Notch signaling pathway is a main
pathway through cell-cell interactions, which regulates the
programmed cell death, cellular proliferation, and differen-
tiation in multiple cell systems, and also is an important
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signaling pathway to modulate the balance between prolifer-
ation and differentiation in hematopoietic environment and
is related with the incidence of multiple hematologic malig-
nancies [41]. The Notch pathway is active in myeloma cells,
resulting in increased proliferation, resistance to apoptosis,
and osteolytic activity. MRK003 is a 𝛾-secretase inhibitor
that exhibits promising in vitro preclinical activity in MM
[42]. Also it was shown that blocking the Notch pathway
by DAPT (𝛾-secretase inhibitor) could increase sensitivity to
bortezomib [43].
6.3. Hedgehog Inhibitors. Finally, the Hedgehog (Hh) path-
way is required for cell-fate determination during the embry-
onic life, as well as cell growth and differentiation in the
adult organism, where the inappropriate activation has been
implicated in several cancers, including MM [44]. NVP-
LDE225, a novel synthetic smoothened (SMO) antagonist
currently in clinical development, decreasesMMcell viability
in vitro by inducing specific downregulation of Hh pathway
[45].
7. Cell Cycle Inhibitors
Myeloma is characterized by genetic instability and disrup-
tion of cell cycle checkpoints, which may render myeloma
cells susceptible to induction of apoptotic death in mitosis,
when the mitotic machinery can be further disrupted [46].
7.1. Cyclin-Dependent Kinases Inhibitors. Cell cycle regula-
tors, such as cyclin-dependent kinases (CDKs), are appealing
targets for MM therapy given the increased proliferative
rates of tumor cells in advanced versus early stages of
MM [47]. Specific inhibition of CDK4/6 by PD-0332991,
an orally bioavailable small-molecule CDK inhibitor, has
demonstrated only growth arrest inMMcells [48], suggesting
that selective CDK inhibition may not be sufficient for
inducing MM cell death. Rather, effective MM cytotoxicity
may be best achieved when multiple CDKs are inhibited
concurrently, as demonstrated in preclinical studies with
multitargeted CDK inhibitors, such as seliciclib [49] and
LCQ195 [50].
7.2. Aurora Kinases Inhibitors. The aurora kinase is a target in
MM because it has been shown to inhibit the growth of MM
cell lines and regulate cell cycle transit from G2 through to
cytokinesis [51]. A novel aurora-A kinase inhibitor MLN8237
showed to induce cytotoxicity and cell-cycle arrest in MM
[52].
8. Targeting the BM Microenvironment
In MM, the impact of tumor microenvironmental factors
such as hypoxia, angiogenesis, and interactions betweenMM
and bone marrow stromal cells have become an important
consideration for understanding disease progression and
resistance to therapy and have been incorporated into novel
drug screening approaches [3]. Key molecules that medi-
ate MM-extracellular matrix (ECM) adhesion are integrins
(predominantly 𝛼5𝛽1 and 𝛼4𝛽1) with the involvement of
syndecan-1, CD44 variants, and the receptor for hyaluronan-
mediated motility (RHAMM) which mediate interactions
with hyaluronan and the SDF-1/CXCR4 axis [53].
8.1. Hypoxia. Studies have indicated that the hypoxic
microenvironment contributes to progression and hypoxia
was also related to induce drug resistance in MM [54].
Hypoxia-inducible transcription factor-1 (HIF-1𝛼) is overex-
pressed in MM cells within the hypoxic microenvironment
and then HIF-1𝛼 inhibition by a lentivirus short hairpin
RNA pool showed that HIF inhibition blocks MM-induced
angiogenesis and reduces MM tumor burden and bone
destruction in vivo, supporting HIF-1𝛼 as a potential
therapeutic target inMM [55]. TH-302 is a hypoxia-activated
prodrugwhich exhibits hypoxia-selective cytotoxicity against
a broad spectrum of human cancer cell lines in vitro, and it
was shown that the TH-302 selectively targets hypoxic MM
cells and improves multiple disease parameters in vivo [56].
8.2. Angiogenesis. The process of angiogenesis, which plays
an important role in the progression of tumors, is governed by
a balance between proangiogenic and antiangiogenic factors
(includingmembers of the fibroblast growth factor (FGF) and
vascular endothelial growth factor (VEGF) families), where
an imbalance of these factors activates an “angiogenic switch”
[57].The development ofMM involves genetic changes in the
tumor cell as well as selective conditions by the BMmicroen-
vironment, such as BM angiogenesis [58]. It is suggested that
MGUS and nonactive MM in which the tumor growth is
arrested are “avascular phases” of plasma cell tumors, while
the active MM is the “vascular phase,” which is associated
with clonal expansion and epigenetic modifications of the
microenvironment as well as the “angiogenic switch” [59].
VEGF is upregulated in MM, and thalidomide has been part
of the standard treatment for MM and is thought to inhibit
VEGF-associated angiogenesis [60]. Bevacizumab, a mono-
clonal antibody directed against VEGF-A, inhibits VEGF and
it has been used in the clinical practice against several types
of solid malignancies [61], and also antiangiogenic therapy
was tested inMM, although the results with this strategy have
been disappointing [62]. A phase II trial of 21 MM patients
with the use of pazopanib, a multitargeted receptor tyrosine
kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-
a/b, and c-kit, showed no clinical responses [63]. Similarly,
in a phase II trial of vandetanib (formerly ZD6474), a small
molecule receptor tyrosine kinase inhibitor of both VEGFR
and epidermal growth factor receptor (EGFR), no responses
were found among 18 patients with relapsedMM [64]. Also a
small molecule VEGFR-2 inhibitor, SU5416, was tested in 27
patients with advancedMM, and no objective responses were
observed [65].
8.3. Integrins. MM cells exhibit preferred adhesion towards
several ECM constituents, including laminin, the microfib-
rillar collagen type-VI, and fibronectin (FN), via 𝛽1 integrin-
mediated adhesion [66]. The predominant cellular receptor
for FN is the 𝛼5𝛽1 integrin (also designated CD49e or
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VLA-5), which is expressed by normal plasma cells, and
in most primary MM samples at the initial stages of the
disease, however, with the progression of MM, there is a
significant downregulation of the 𝛼5𝛽1 integrin [67]. Several
signaling responses are activated by microenvironmental
interactions, affecting the survival, proliferation, and migra-
tion of MM cells. An important consequence of these direct
adhesive interactions between the BM/ECM and MM cells
is the development of drug resistance. This phenomenon is
termed “cell adhesion-mediated drug resistance” (CAM-DR)
and it is thought to be one of the major mechanisms by
which MM cells escape the cytotoxic effects of therapeutic
agents [68]. VLA-4 or 𝛼4𝛽1 integrin is a critical molecule
for the induction of CAM-DR in MM cells, and it was
shown that bortezomib enhances the effects of conventional
antimyeloma agents by overcoming VLA-4-mediated CAM-
DR, and bortezomib-based combination chemotherapy can
improve the treatment outcome of patients with MM [69].
8.4. CD44. Other types of adhesion receptors of MM cells
may also be targeted by therapeutic antibodies. The CD44v6
variant which is expressed by MM cells and mediates their
adhesion to hyaluronan can be inhibited by bivatuzumab,
a humanized monoclonal antibody directed against this
variant, coupledwith the highly potent antimicrotubule agent
mertansine [70]. Another alternative to block MM cells
interactions with hyaluronan includes a peptide containing
hyaluronan binding motifs which can inhibit cancer cells
growth. A novel therapeutic approach towards hyaluronan
binding protein was demonstrated by immunization of MM
patients with a highly immunogenic CD8(+) T-cell epitope
peptide derived from RHAMM [71].
8.5. CXCR4. CXCR4, a cell surface chemokine receptor,
binds and responds to cytokines of the CXC chemokine
family such as a CXCL12 (or SDF-1), and it has a wide
cellular distribution including lymphocytes, hematopoietic
stem cells, endothelial and epithelial cells, and cancer cells
[72]. SDF-1 is produced by BM-derived stromal cells, and its
receptor CXCR4 is expressed on the surfaces of normal cells
and MM cells. The SDF-1/CXCR4 axis is a key regulator of
MM cell homing, adhesion, and motility [73]. CXCR4 antag-
onist AMD3100 was found to be powerful antagonist of the
SDF-1 receptor CXCR4, by blocking MM cells interactions
with the BM microenvironment and consequent signaling
responses and enhancing their sensitivity to therapy [74].
Targeting malignant cell trafficking would lead to new ther-
apeutic approaches in MM and other malignancies, where
it will alter the capacity of malignant cells to interact with
their protective microenvironment by disrupting adhesion
and inducing mobilization, leading to increased sensitivity
to therapeutic agents [74]. In a phase I trial of plerixafor
and bortezomib as a chemosensitization strategy in relapsed
or relapsed/refractory multiple myeloma preliminary results
showed that the combination is well-tolerated with encour-
aging results showing that MM cells can be separated from
their protective stromal environment which may make them
more sensitive to chemotherapy, based on 8% CR and 8%
MR, with anOR of 16% in this relapsed/refractory population
[75]. CXCR4 was shown to induce MM cell migration via
signaling through Rho GTPases; RhoA and Rac1 were shown
to play key roles in SDF1-induced adhesion of MM cells
to BM stromal cells, and inhibition by small molecule-
specific inhibitors for Rac1 GTPase and for ROCK (the main
effector protein downstreamof RhoA) showed that RhoAwas
important for both adhesion and chemotaxis, whereas Rac1
was important for adhesion but not chemotaxis in MM [76].
8.6. Selectins. Selectins are cell adhesion proteins involved
in extravasation and homing of leukocytes to target organs
[77]. PSGL-1 was highly expressed onMM cells and regulates
the interaction of MM cells with cells in the BM microen-
vironment including endothelial cells and BM stromal cells.
Using pan-selectin inhibitor GMI-1070, it was shown that
PSGL-1 regulates the activation of integrins and MM-cell
proliferation in coculture with endothelial and stromal cells.
The inhibition of this interaction with GMI-1070 sensitized
MM cells to bortezomib in vitro and in vivo [78].
9. Conclusions
Cell signaling targeted therapies (HDAC, PI3K/AKT/mTOR,
p38 MAPK, Hsp90, Wnt, Notch, Hedgehog, and cell
cycle) and strategies targeting the tumor microenviron-
ment (hypoxia, angiogenesis, integrins, CD44, CXCR4, and
selectins) have yielded promising results alone or in com-
binations in preclinical or clinical studies involving patients
with relapsed/refractory MM. Although these novel targeted
therapies have improved outcomes for MM patients, a better
understanding of the complex drug resistance in MM is
required and further development of new therapeutic agents
is warranted.
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